Gold prices edge higher on raised Fed rate cut hopes
SAN DIEGO - TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), has announced a License and Supply Agreement with Quantoom Biosciences, which will enable the integration of TriLink’s CleanCap mRNA capping technology into Quantoom’s Ntensify (sa)mRNA production platform. According to InvestingPro data, Maravai maintains a strong liquidity position with a current ratio of 5.96, though the company faces challenges with revenue declining 11.76% over the last twelve months. This partnership aims to expedite the production of mRNA-based vaccines and therapeutics, particularly for developing countries and regions with limited access to essential medicines.
The CleanCap technology is known for its high efficiency in creating optimal cap structures for mRNA, boasting over 95% efficiency. This co-transcriptional capping solution is expected to significantly enhance mRNA yield and reduce process time compared to traditional capping methods. Despite technological advantages, InvestingPro analysis reveals the company faces profitability challenges, with negative EBITDA of $39.89 million in the last twelve months. InvestingPro subscribers have access to 8 additional key insights about Maravai’s financial health and market position. With this technology, Quantoom’s customers will be able to improve the development of their (sa)mRNA drugs through clinical phases.
Becky Buzzeo, Chief Commercial Officer at Maravai, highlighted the importance of industry collaborations in strengthening global health and combating infectious diseases. She expressed enthusiasm for the potential of TriLink’s CleanCap reagents to facilitate the delivery of critical therapeutics and vaccines to resource-limited nations.
TriLink’s CleanCap technology has been a game-changer since its introduction in 2017, being incorporated into the majority of approved COVID-19 mRNA and saRNA vaccines. José Castillo, CEO of Quantoom Biosciences, emphasized the company’s commitment to making RNA technology more accessible and scalable. The partnership with TriLink is a strategic move to empower researchers and manufacturers in creating life-saving vaccines and therapeutics for communities in need.
TriLink BioTechnologies is a global leader in nucleic acid and mRNA solutions, providing comprehensive services and materials to the pharmaceutical industry, including CleanCap mRNA capping technology. Maravai LifeSciences, TriLink’s parent company, supplies critical products for drug therapies, diagnostics, and novel vaccine development.
Quantoom Biosciences offers a full-stack RNA partnership for mRNA- and saRNA-based vaccines and therapeutics. Its Ntensify solution, launched in 2023, has been recognized for its performance and user-friendliness in scalable RNA production. Market sentiment toward Maravai has been challenging, with the stock down over 75% in the past year. For detailed analysis and comprehensive insights, including Fair Value estimates and growth projections, explore Maravai’s full research report on InvestingPro, part of our coverage of over 1,400 US stocks.
The information in this article is based on a press release statement.
In other recent news, Maravai LifeSciences Holdings Inc. reported its first-quarter 2025 earnings with revenue reaching $47 million, surpassing the expected $45.6 million. However, the company posted an earnings per share (EPS) of -$0.08, missing the forecast of -$0.07. This revenue beat comes amid a challenging financial landscape, as S&P Global Ratings downgraded Maravai to ’B-’ from ’B’, highlighting a significant decline in revenue and EBITDA due to a halt in high-volume mRNA vaccine-related sales. The company’s EBITDA was negative $10.6 million for the first quarter, compared to a positive $8 million in the same period last year. Maravai’s total sales for 2025 are projected to be around $195 million, a drop from the previously forecasted $265 million, largely due to customers having sufficient vaccine inventory. Despite these challenges, Maravai continues to innovate, launching new products like the Poly A plus line and CRISPR guides. Additionally, the company recently held its Annual Meeting of Shareholders, where four directors were elected to the board, and Ernst & Young LLP was ratified as the independent registered public accounting firm for 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.